Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Advertisement
Hematocrit control was “suboptimal” in more than half of patients with high-risk polycythemia vera.
Ruben Mesa, MD, discusses his career in MPN treatment and research and notable abstracts at the 2022 ASH Annual Meeting.
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Patients with MPN have a high risk of death from cardiovascular causes.
Patients with MPN who are employed face a “high economic burden,” especially if they experience thrombotic events.
Statin use may reduce the risk of developing a myeloproliferative neoplasm (MPN), according to a recent study.
Advertisement
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Srdan Verstovsek, MD, discusses the phase III VERIFY trial of rusfertide in patients with polycythemia vera.
Whole blood mutation allele frequency had only weak prognostic value in certain patients with polycythemia vera.
Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms.
Symptom-related quality of life is linked with the type of cytoreductive treatment used for MPNs.
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Long-term follow-up results of a phase II study of ruxolitinib in patients with MPNs were presented at the 2022 ASH Meeting.
New data support the use of ropeginterferon alfa-2b therapy in patients with low-risk or high-risk PV,
An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly.
IFNα2 treatment may help reduce the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
The National Comprehensive Cancer Network publishes new MPN guidelines.
Researchers published new classifications for MPNs and acute leukemias.
Transfusion independence was associated with improved survival in studies of momelotinib in patients with myelofibrosis.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726